is this the real deal, page-5

That's a fairly generous interpretation of what seems a pretty clear statement. But unfortunately, even if JoanJoan is right, the statement by Aquarian would still be wrong. It is already clear that Apricitabine is not a resistance-free treatment. Like other NRTIs, some strains are clearly resistant to it, to one degree or another. Fortunately for Avexa, the level of resistance against Apricitabine is generally lower than for other drugs in the same class, and there are fewer mutants identified that are 'fully' resistant. Again, though, I still support those arguing Avexa is looking very good, if not always for the reasons they put forward.